Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
24/06/2026 02:29
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly June 24 (Reuters) - Abbisko Cayman 2256.HK said on Wednesday that its Shanghai-based unit Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly LLY.N.
The agreement will allow both firms to collaborate on the discovery and development of medicines across multiple targets, with Abbisko Therapeutics eligible for development, regulatory and commercial milestone payments of up to $1.9 billion.
(Reporting by Nichiket Sunil in Bengaluru; Editing by Subhranshu Sahu)
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration